List view / Grid view
In this Q&A, Dr Murray Cairns, NHMRC Leadership Research Fellow at the University of Newcastle, shares his insights about the genetic influences on circulating retinol, and explains how a retinol polygenic score could be utilised in a precision medicine approach.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have developed the world’s first animal model with A-to-G mtDNA edits achieved using engineered TALEDs.
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
Using tumour organoids, researchers identified that overexpression of Engrailed-1 blocked genes associated with natural cell death.
By studying the molecular cell states within transplanted paediatric hearts, researchers have unlocked new treatment strategies.
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
Using phosphoproteomics, the calcium channel Cav2.3 was found as a target to treat a type of genetic epilepsy, CDKL5 deficiency disorder.
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities.
A new discovery about a different protective genetic mutation in apolipoprotein L1 could have major implications for kidney health.
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
